Fermenta Biotech Ltd
₹ 335
-0.03%
12 Jun
- close price
About
Incorporated in 1951, Fermenta Biotech
Ltd manufactures Active Pharmaceutical Ingredient, Aqua CHL, Biotechnology and Nutraceutical products[1]
Key Points
- Market Cap ₹ 986 Cr.
- Current Price ₹ 335
- High / Low ₹ 449 / 163
- Stock P/E 14.6
- Book Value ₹ 129
- Dividend Yield 0.37 %
- ROCE 18.7 %
- ROE 19.5 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
- Promoter holding has increased by 2.03% over last quarter.
Cons
- Stock is trading at 2.59 times its book value
- The company has delivered a poor sales growth of 7.54% over past five years.
- Company has a low return on equity of 6.07% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 | 14 | 6 | 6 | 13 | 403 | 299 | 371 | 387 | 328 | 307 | 431 | |
| 11 | 11 | 12 | 14 | 22 | 255 | 229 | 276 | 310 | 288 | 269 | 330 | |
| Operating Profit | 4 | 3 | -6 | -8 | -9 | 148 | 70 | 95 | 77 | 39 | 38 | 100 |
| OPM % | 28% | 21% | -99% | -154% | -75% | 37% | 24% | 26% | 20% | 12% | 12% | 23% |
| 0 | 0 | 1 | 0 | 0 | 6 | 12 | 6 | 8 | -51 | -1 | 12 | |
| Interest | 0 | 0 | 2 | 6 | 11 | 21 | 20 | 19 | 18 | 21 | 17 | 14 |
| Depreciation | 2 | 2 | 2 | 3 | 4 | 12 | 15 | 19 | 24 | 24 | 24 | 23 |
| Profit before tax | 2 | 1 | -9 | -18 | -23 | 121 | 48 | 63 | 43 | -58 | -5 | 74 |
| Tax % | 31% | 30% | -1% | 2% | 3% | 9% | -34% | 18% | 29% | -2% | 307% | 9% |
| 1 | 1 | -9 | -18 | -24 | 110 | 64 | 52 | 30 | -57 | -19 | 68 | |
| EPS in Rs | 0.51 | 0.26 | -3.31 | -6.63 | -8.75 | 40.13 | 21.63 | 17.66 | 10.27 | -19.37 | -6.37 | 22.98 |
| Dividend Payout % | 161% | 157% | -6% | -3% | -2% | 1% | 23% | 14% | 12% | -6% | -19% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 41% |
| 5 Years: | 8% |
| 3 Years: | 4% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 57% |
| 5 Years: | 2% |
| 3 Years: | 31% |
| TTM: | 975% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 4% |
| 3 Years: | 19% |
| 1 Year: | 90% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 |
| Reserves | 91 | 90 | 80 | 87 | 62 | 245 | 298 | 356 | 382 | 322 | 300 | 365 |
| 25 | 35 | 52 | 44 | 143 | 209 | 226 | 234 | 241 | 219 | 139 | 115 | |
| 13 | 15 | 15 | 12 | 15 | 93 | 71 | 78 | 76 | 108 | 112 | 128 | |
| Total Liabilities | 131 | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 664 | 565 | 622 |
| 8 | 7 | 93 | 94 | 96 | 177 | 197 | 250 | 287 | 257 | 267 | 226 | |
| CWIP | 34 | 63 | 1 | 1 | 0 | 22 | 71 | 57 | 35 | 45 | 2 | 16 |
| Investments | 39 | 40 | 41 | 40 | 118 | 8 | 1 | 13 | 13 | 15 | 4 | 4 |
| 51 | 33 | 15 | 12 | 9 | 344 | 341 | 363 | 378 | 347 | 293 | 377 | |
| Total Assets | 131 | 143 | 149 | 146 | 223 | 551 | 610 | 683 | 713 | 664 | 565 | 622 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | -0 | -5 | -9 | 1 | 91 | 30 | 63 | 50 | 124 | 105 | 34 | |
| -20 | -11 | -8 | 20 | -89 | -97 | -39 | -44 | -32 | -63 | -15 | 0 | |
| 21 | 9 | 14 | -13 | 88 | 12 | -48 | -1 | -22 | -41 | -91 | -51 | |
| Net Cash Flow | 2 | -2 | 1 | -2 | 1 | 6 | -57 | 18 | -4 | 19 | -1 | -17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 9 | 5 | 2 | 26 | 8 | 59 | 94 | 95 | 111 | 75 | 92 | 102 |
| Inventory Days | 347 | 501 | 392 | 328 | 317 | 272 | 249 | |||||
| Days Payable | 172 | 208 | 135 | 115 | 150 | 184 | 169 | |||||
| Cash Conversion Cycle | 9 | 5 | 2 | 26 | 8 | 234 | 387 | 352 | 324 | 242 | 180 | 181 |
| Working Capital Days | -212 | -923 | -2,380 | -538 | -289 | 97 | 225 | 191 | 208 | 130 | 133 | 132 |
| ROCE % | 2% | 1% | -5% | -9% | -7% | 45% | 13% | 14% | 10% | 4% | 4% | 19% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Investor Presentation 4 Jun
-
Clarification On Record Date
29 May - Record date fixed as August 6, 2025 for FY 2024-25 final equity dividend payment.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
29 May - Newspaper publication - Annual financial results for the year ended March 31, 2025
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Annual secretarial compliance report confirms full regulatory adherence for FY ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
28 May - Fermenta reports FY25 revenue INR 481.3cr (+39%), net profit INR 76.4cr, strong volume growth, new product validations.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Jun 2025TranscriptNotesPPT
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
Jun 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Feb 2022TranscriptNotesPPT
-
Dec 2021Transcript PPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jul 2021Transcript PPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021Transcript PPT
-
Feb 2021TranscriptNotesPPT
-
Dec 2020Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Dec 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Sep 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
Business Overview:[1][2]
a) FBL is engaged in development
and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries. It is a global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
b) Company is involved in manufacturing
of APIs for muscle relaxant and anti-flatulent applications. It delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment & management.
c) Also, company has strategic investments in subsidiaries / associate companies primarily dealing in manufacturing and marketing bulk drugs and providing services of sporting and health awareness activities / education activities.
d) Company also deals in lease rental business for ITES properties developed in Than